Cargando…

A randomized, controlled, feasibility study of RD‐X19 in subjects with mild‐to‐moderate COVID‐19 in the outpatient setting

The RD‐X19 is an investigational, handheld medical device precisely engineered to emit blue light through the oral cavity to target the oropharynx and surrounding tissues. At doses shown to be noncytotoxic in an in vitro three‐dimensional human epithelial tissue model, the monochromatic visible ligh...

Descripción completa

Detalles Bibliográficos
Autores principales:	Stasko, Nathan, Cockrell, Adam S., Kocher, Jacob F., Henson, Ibrahim, Emerson, David, Wang, Ye, Smith, Jonathan R., Henderson, Nathan H., Wood, Hillary, Bradrick, Shelton S., Jones, Terry, Santander, Jorge, McNeil, John G.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2022
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9099126/ https://www.ncbi.nlm.nih.gov/pubmed/35137532 http://dx.doi.org/10.1111/cts.13249

Ejemplares similares

Visible blue light inhibits infection and replication of SARS-CoV-2 at doses that are well-tolerated by human respiratory tissue
por: Stasko, Nathan, et al.
Publicado: (2021)

New Therapeutic Options in Mild Moderate COVID-19 Outpatients
por: Ucciferri, Claudio, et al.
Publicado: (2022)

Causes and Consequences of Flavivirus RNA Methylation
por: Bradrick, Shelton S.
Publicado: (2017)

Clinical characteristics and viral load dynamics of COVID-19 in a mildly or moderately symptomatic outpatient sample
por: Caplan, Amanda, et al.
Publicado: (2021)

Oral bemnifosbuvir (AT-527) vs placebo in patients with mild-to-moderate COVID-19 in an outpatient setting (MORNINGSKY)
por: Horga, Arantxa, et al.
Publicado: (2023)

1349. Unveiling the Link between COVID-19 and the Gut Microbiome in an Outpatient Cohort with Mild to Moderate Illness
por: Comba, Isin Y, et al.
Publicado: (2023)

Neuroanatomical Moderators of the Impact of Mild Behavioral Impairment on Cognition
por: Rouse, Hillary, et al.
Publicado: (2021)

Efficacy and hazards of 425 nm oral cavity light dosing to inactivate SARS-CoV-2
por: Stockslager, Max A., et al.
Publicado: (2022)

Mild to moderate COVID-19 illness in adult outpatients: Characteristics, symptoms, and outcomes in the first 4 weeks of illness
por: Blair, Janis E., et al.
Publicado: (2021)

Azithromycin for mild-to-moderate COVID-19
por: Patel, Jigar, et al.
Publicado: (2021)

Identification of Gemin5 as a Novel 7-Methylguanosine Cap-Binding Protein
por: Bradrick, Shelton S., et al.
Publicado: (2009)

Incidence of Vascular Thromboembolic Events in Outpatients with Mild COVID-19
por: Eswaran, Harish, et al.
Publicado: (2020)

Hydroxychloroquine with or without Azithromycin in Mild-to-Moderate Covid-19
por: Cavalcanti, Alexandre B., et al.
Publicado: (2020)

Features of Mild-to-Moderate COVID-19 Patients With Dysphonia
por: Lechien, Jerome R., et al.
Publicado: (2022)

Azithromycin for mild-to-moderate COVID-19 – Authors' reply
por: Hinks, Timothy S C
Publicado: (2021)

Neurological manifestations in mild and moderate cases of COVID-19
por: Abdel Azim, Ghada Saed, et al.
Publicado: (2021)

Bamlanivimab plus Etesevimab in Mild or Moderate Covid-19
por: Dougan, Michael, et al.
Publicado: (2021)

Kidney outcome after mild to moderate COVID-19
por: Schmidt-Lauber, Christian, et al.
Publicado: (2023)

A miRNA-responsive cell-free translation system facilitates isolation of hepatitis C virus miRNP complexes
por: Bradrick, Shelton S., et al.
Publicado: (2013)

Oral antivirals for mild–moderate COVID-19: a panacea or a logistical and clinical conundrum?
por: Coombes, Ian D, et al.
Publicado: (2022)

A Framework for Outpatient Infusion of Antispike Monoclonal Antibodies to High-Risk Patients with Mild-to-Moderate Coronavirus Disease-19: The Mayo Clinic Model
por: Razonable, Raymund R., et al.
Publicado: (2021)

Impact of Meditation–Based Lifestyle Modification on HRV in Outpatients With Mild to Moderate Depression: An Exploratory Study
por: Bringmann, Holger C., et al.
Publicado: (2022)

The hepatitis C virus 3′-untranslated region or a poly(A) tract promote efficient translation subsequent to the initiation phase
por: Bradrick, Shelton S., et al.
Publicado: (2006)

Hydrothermotherapy in prevention and treatment of mild to moderate cases of COVID-19
por: Ramirez, Francisco E., et al.
Publicado: (2021)

Hydroxychloroquine with azithromycin in patients hospitalized for mild and moderate COVID-19
por: Lamback, Elisa Baranski, et al.
Publicado: (2021)

Newly diagnosed diabetes in patients with mild to moderate COVID-19
por: Sathish, Thirunavukkarasu, et al.
Publicado: (2021)

The Musculoskeletal Involvement After Mild to Moderate COVID-19 Infection
por: dos Santos, Patty K., et al.
Publicado: (2022)

Bamlanivimab for Mild to Moderate COVID-19 in Kidney Transplant Recipients
por: Jan, Muhammad Y., et al.
Publicado: (2021)

Psychological effect of mild to moderate COVID-19 on hospitalised patients
por: Aziz, Sadaf, et al.
Publicado: (2022)

Mild-to-Moderate Croup Presentations in Patients With COVID-19 Infection
por: Mathew, Danica, et al.
Publicado: (2022)

The Impact of Isolation on Elderly Patients with Mild to Moderate COVID-19
por: Sugiyama, Mizuki, et al.
Publicado: (2022)

Mild Hyperglycaemia in Hospitalised Children with Moderate COVID-19 Infection
por: Vojtková, Jarmila, et al.
Publicado: (2023)

Novel outpatient management of mild to moderate COVID-19 spares hospital capacity and safeguards patient outcome: The Geneva PneumoCoV-Ambu study
por: Chevallier Lugon, Chloé, et al.
Publicado: (2021)

Oral nano‐curcumin formulation efficacy in the management of mild to moderate outpatient COVID‐19: A randomized triple‐blind placebo‐controlled clinical trial
por: Ahmadi, Reza, et al.
Publicado: (2021)

LB1528C. Ivermectin for Treatment of Mild-to-Moderate COVID-19 in the Outpatient Setting A Decentralized, Placebo-controlled, Randomized, Platform Clinical Trial
por: Naggie, Susanna
Publicado: (2022)

Prediction of the Rehabilitation Duration and Risk Management for Mild-Moderate COVID-19
por: Zheng, Qiong-Na, et al.
Publicado: (2020)

High prevalence of occult thrombosis in cases of mild/moderate COVID-19
por: Chen, Budong, et al.
Publicado: (2021)

Combined Metabolic Activators Accelerates Recovery in Mild‐to‐Moderate COVID‐19
por: Altay, Ozlem, et al.
Publicado: (2021)

Cognitive Impairment in Non-critical, Mild-to-Moderate COVID-19 Survivors
por: Henneghan, Ashley M., et al.
Publicado: (2022)

The importance of early detection of ENT symptoms in mild-to-moderate COVID-19
por: Spinato, Giacomo, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_0ilp1n7l24i5p5pfk6c3locmn0